Rafferty Asset Management, LLC - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$8,449,624
+253.0%
1,104,526
+244.7%
0.05%
+284.6%
Q2 2023$2,393,485
-20.3%
320,413
-28.8%
0.01%
-35.0%
Q1 2023$3,001,380
-34.7%
449,982
-24.5%
0.02%
-47.4%
Q4 2022$4,595,677
+150.3%
596,067
+245.5%
0.04%
+90.0%
Q3 2022$1,836,000
+65.1%
172,526
+26.3%
0.02%
+100.0%
Q2 2022$1,112,000
+49.9%
136,626
+31.8%
0.01%
+150.0%
Q1 2022$742,000
-89.0%
103,649
-73.8%
0.00%
-88.9%
Q4 2021$6,769,000
+332.5%
395,134
+480.9%
0.04%
+227.3%
Q3 2021$1,565,00068,0210.01%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders